3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Renal Cell
2
Triple Negative Breast Neoplasms
1
Kidney Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
aldesleukin
22
Sunitinib
21
Bevacizumab
16
Interleukin-2
14
Everolimus
14
Interferon-alpha
13
Gemcitabine
13
Cyclophosphamide
13
fludarabine phosphate
11
Peripheral Blood Stem Cell Transplantation
9
Sorafenib
8
Filgrastim
8
Axitinib
8
Nivolumab
7
pembrolizumab
6
Ipilimumab
6
Doxorubicin
6
Carboplatin
6
sargramostim
5
cabozantinib
5
Capecitabine
5
Thalidomide
4
Tacrolimus
4
Radiotherapy
4
Radiosurgery
4
Neoadjuvant Therapy
4
Mycophenolic Acid
4
Magnetic Resonance Spectroscopy
4
Erlotinib Hydrochloride
4
Chemotherapy, Adjuvant
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Kidney Neoplasms
×
CB-839
×
Clear all
NCT03428217
2023-03-20
CANTATA
Calithera Biosciences, Inc
Phase 2
Completed
444 enrolled
15 charts